A Molecular Diagnostics Company
Making Early Cancer Detection the New Standard of Primary Care
Our Mission
For heart disease, thyroid function and diabetes… frequent, recurrent, sequential monitoring and screening are standard of primary care in asymptomatic populations.
Our Science
Find out how we’re unlocking frequent, recurring monitoring for early cancer signal as the new standard of primary care.
More accurate & reliable
More cost effective
fully scalable
significant societal impact
Our Social Impact
Latest News
ENMEDIA Explores Podcast Liquid Biopsy: What’s next?
June 30, 2023
Dr. Giulia Kennedy and Dr. Bernard Peperstraete talk with ENMEDIA about AcuamarkDx's solution to crack early cancer detection (long dash) a potential game changer for the liquid biopsy market.
AcuamarkDx Welcomes Giulia Kennedy, PhD, to the Board of Directors
May 03, 2023
Dr. Kennedy brings more than two decades of experience developing novel diagnostic technologies, most recently served as global chief scientific officer and chief medical officer at Veracyte, a global diagnostics company.
AcuamarkDx Secures $11.3 Million Series A Funding to Advance Innovative Assays for Improved, Cost-Effective Early-Cancer Detection
July 19, 2022
The round was led by Claudio Del Vecchio, former chairman, CEO, and owner of Brooks Brothers Group, Inc. and joined by Bruker Corporation.
